Kercheville Advisors’s Merck MRK Stock Holding History

Kercheville Advisors’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$514K	Hold	4,003	–	–	0.16%	71
2026 Q1	$482K	Buy	4,003 +203	+5%	+$23.4K	0.15%	66
2025 Q4	$415K	Buy	+3,800	New	+$357K	0.11%	84
2023 Q1	–	Sell	-17,952	Closed	-$1.99M	–	82
2022 Q4	$1.99M	Buy	+17,952	New	+$1.83M	1.38%	24

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Kercheville Advisors's MRK Position: Q2 2026 in Review

Kercheville Advisors held its Merck (MRK) position steady in Q2 2026 at 4,003 shares worth $514K. The position accounts for 0.16% of the portfolio, ranked #71.

Kercheville Advisors first reported a position in MRK in Q4 2022 and has held it in 4 quarters since. The position peaked at $1.99M in Q4 2022. 3,841 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Kercheville Advisors held 4,003 shares of Merck worth $514K as of Q2 2026.
Kercheville Advisors left its Merck share count unchanged in Q2 2026.
Merck made up 0.16% of Kercheville Advisors's portfolio in Q2 2026, its #71 holding.
Kercheville Advisors first reported a position in Merck in Q4 2022 and has held it in 4 quarters since.
Kercheville Advisors's Merck position peaked at $1.99M in Q4 2022.
3,841 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Kercheville Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.